Andrew Fraley, Ph.D., co-founder of Korro Bio, holds over 20 years of experience in the field of nucleic acid technologies and therapeutics.
Prior to co-founding Korro, Andrew was a co-founder of Triplet Therapeutics, and a founding executive team member serving as SVP of translational sciences for Trucode Gene Repair, an in vivo gene editing company, leading the company’s scientific strategy and operations. He has also served in key senior leadership roles within the biotech community, including Moderna Therapeutics, enabling the development of modified messenger RNA, and Ensemble Therapeutics, providing leadership for platform development and macrocyclic discovery.
Andrew has authored and reviewed scientific publications and is listed as an inventor on patents in areas including nucleic acid therapeutics, oligonucleotide delivery and macrocyclic drug discovery. He has served as a Boston University Kindle Mentor and has consulted for government organizations, venture firms and biotech startups. He holds a B.A. from DePauw University, earned his Ph.D. in bio-organic chemistry at Boston College and was a Chateaubriand Postdoctoral Research Fellow at the Université de Louis Pasteur.